Table 4. . Chemotherapy in brain metastases.

Chemotherapy	Study	Phase of trial	Patient population	Patients (n)	ORR	OS (months)
Fotemustine vs DTCI	Avril et al. [47]	III	Melanoma	112	15.2%	7.3
Temozolomide	Agarwala et al. [49]	II	Melanoma	151	7%	3.5
Fotemustine + CDDP	Cotto et al. [48]	II	NSCLC	31	28%	4.0
CBDCA + RT vs RT	Guerrieri et al. [50]	III	NSCLC	21	29%	3.7
CDDP + VP16	Franciosi et al. [46]	II	Breast, NSCLC, melanoma	43	30%	8.0
Temozolomide + WBRT vs WBRT	Verger et al. [51]	II	Brain metastases	41	17%	4.5
Temozolomide + WBRT vs WBRT	Antonadou et al. [52]	II	Brain metastases	25	96%	8.6

NSCLC: Non-small-cell lung cancer; ORR: Overall response rate; OS: Overall survival; RT: Radiation therapy; WBRT: Whole-brain radiotherapy.